| Document |
Document Title |
|
WO/2024/099592A1 |
The present invention relates to a spinach plant that is resistant to downy mildew caused by Peronospora farinosa. The present invention further relates to a resistance gene that confers resistance to downy mildew in spinach plants and m...
|
|
WO/2024/102988A1 |
This document relates to methods and materials for treating a mammal (e.g., a human) having, or at risk of developing, a proteinopathy. For example, one or more nucleoporin polypeptides (and/or nucleic acids designed to express a nucleop...
|
|
WO/2024/102604A1 |
Anti-5T4 antibodies and antigen-binding fragments thereof and chimeric antigen receptors (CARs) comprising anti-5T4 antigen-binding domains are described. Also described are nucleic acids encoding the antibodies and CARs, compositions co...
|
|
WO/2024/099273A1 |
Provided are a fusion protein and a composition, a kit, a granulated antigen, a vaccine, and a pharmaceutical composition comprising same. The present invention also relates to use of the fusion protein and the composition, the kit, and ...
|
|
WO/2024/102746A1 |
Methods are described for treating neurotrophic keratitis in a subject by administering an agent that inhibits fidgetin-like 2 activity, such as by using an RNA interference agent, e.g., siRNA.
|
|
WO/2024/006281A3 |
The present disclosure pertains to modified immune cells comprising chimeric switch receptors and methods of using and making immune cells comprising chimeric switch receptors. The present disclosure also pertains to modified immune cell...
|
|
WO/2024/098361A1 |
The present application relates to the technical field of bio-pharmaceuticals. The present application particularly relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3'-untranslate...
|
|
WO/2024/064637A3 |
Compositions comprising an RNA molecule comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-11121 and methods and uses thereof.
|
|
WO/2024/099575A1 |
The present invention relates to artificial nucleic acids for site-directed editing of a target RNA. In particular, the present invention relates to artificial nucleic acids which provide for enhanced editing specificity and avoid undesi...
|
|
WO/2024/102644A1 |
The present disclosure provides compositions and methods related to the co-localization of chimeric proteins on a cell surface. In particular, the present disclosure provides methods and compositions for facilitating the cell-surface co-...
|
|
WO/2024/102688A1 |
Compositions and uses thereof are provided for treating an osteoclastogenesis-related disease, bone or joint destruction, bone-related impaired mobility, osteoporosis, and/or rheumatoid arthritis. The compositions comprise an agent which...
|
|
WO/2024/102913A1 |
The present disclosure provides methods of treating a subject having a kidney disease or preventing a subject from developing a kidney disease by administering an Angiopoietin Like 3 (ANGPTL3) inhibitor and a Solute Carrier Family 5 Memb...
|
|
WO/2024/102360A1 |
Devices for isolating, collecting and/or transferring target molecules to an assay area, comprising an enclosure having a top section adapted to receive a sample, a central hollow body section or other area or cavity suitable for receivi...
|
|
WO/2024/092967A1 |
The present invention relates to the technical field of enzyme engineering, and in particular, to a rare earth-dependent alcohol dehydrogenase mutant and use thereof. According to the present invention, a method combining the MutCompute ...
|
|
WO/2024/097713A1 |
In one embodiment, the present disclosure provides hypoallergenic peanut allergens Ara h 6 variants wherein at least one epitope recognized by anti-Ara h 6 antibodies has been modified, thereby having reduced or abolished antibody bindin...
|
|
WO/2024/097315A2 |
Methods of profiling cells for donor capability with a recipient subject are provided. In particular, methods relating to identifying cells, such as T cells, suitable for making a cell therapy product and administration to a patient (e.g...
|
|
WO/2024/094009A1 |
The present invention provides an expression cassette for a target gene and use thereof. Specifically, the present invention provides an expression cassette having elements such as HCR, DSE, TPL and eMlp, an encoding nucleic acid thereof...
|
|
WO/2024/093522A1 |
The present disclosure relates to methods, compositions, and kits for concentrating and purifying one or more target analyte (s) from a bulk fluid sample. In some embodiments, the methods involve at least two first aqueous two-phase syst...
|
|
WO/2024/097899A1 |
Polynucleotides, expression constructs, compositions, kits and method relating to genetic disorders are disclosed. Some embodiments provided herein encompass variants of a protein that relate to a genetic disorder. Also contemplated are ...
|
|
WO/2024/092740A1 |
Provided is a method for detecting intercellular interaction. The method comprises: (1) preparing a first cell expressing a TCR activation response element and a reporter molecule, the first cell expressing a TCR; (2) co-incubating an an...
|
|
WO/2024/097655A1 |
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated amino acid sequence encoded by mutated CDKN2A. The TCRs may recognize mutated CDKN2A peptide presented by an HLA-A molecu...
|
|
WO/2024/098061A2 |
This disclosure relates to methods and compositions for treating heart failure (e.g., reducing or inhibiting cardiomyocyte hypertrophy or by increasing utilization of fatty acids as an energy source and Fatty Acid oxidation in cardiomyoc...
|
|
WO/2024/093523A1 |
The present disclosure relates to methods, compositions, and kits for isolating target nucleic acids below a target size from a sample comprising nucleic acid components. In some embodiments, the methods involve one or more aqueous two-p...
|
|
WO/2024/096125A1 |
The present disclosure provides a technique for efficiently designing or producing a bacterial preparation utilizing a bacterium capable of exhibiting a desired trait or a desired efficacy. More specifically, the present disclosure provi...
|
|
WO/2024/097276A1 |
This document relates to methods and materials involved in treating cancer. For example, methods and materials for using chimeric antigen receptor (CAR) T cells having reduced levels of an interleukin (IL) 4 polypeptide, having reduced l...
|
|
WO/2024/097521A2 |
In some aspects, the disclosure relates to compositions and methods for modulating (e.g., increasing and/or decreasing) expression of COL1A1 or COL1A2 in a subject. In some aspects, the disclosure provides isolated nucleic acids, and vec...
|
|
WO/2024/093519A1 |
The present disclosure relates to methods, compositions, and kits for concentrating and purifying at least one target analyte from a clinical biological sample. In some embodiments, the methods involve one or more aqueous two-phase syste...
|
|
WO/2024/093652A1 |
The present invention discloses a nanobody targeting IL-6Rα protein and uses thereof, wherein the heavy chain variable region of the nanobody comprises three complementary determining regions, CDR1, CDR2, and CDR3, wherein CDR1 has an a...
|
|
WO/2024/095964A1 |
The present invention addresses the problem of developing an antibody-drug complex containing a TLR7/8 dual agonist compound or a salt thereof to provide a pharmaceutical composition used for the prevention or treatment of various types ...
|
|
WO/2024/097737A1 |
The present disclosure relates to compositions and methods for treating blood vessel epicardial substance (BVES) protein-related disorders.
|
|
WO/2024/096217A1 |
The present invention relates to a modified microorganism of the genus Corynebacterium producing L-glutamic acid and a method for producing L-glutamic acid using same, more specifically to a novel variant of biotin-protein ligase involve...
|
|
WO/2024/092375A1 |
The invention discloses a method for preparing a composition of mitochondria isolated from umbilical cord mesenchymal stromal cells (UC-MSC) and enriched with mitochondrial antiviral-signalling (MAVS) protein, and the use of this composi...
|
|
WO/2024/097814A1 |
The invention provides methods for upregulating mitochondrial and/or glycolytic metabolism in T cells by increasing the flux of pyruvate into the citric acid cycle, thereby increasing mitochondrial and/or glycolytic metabolism. In genera...
|
|
WO/2024/097900A1 |
RNA molecules comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-2325 and compositions, methods, and uses thereof.
|
|
WO/2024/096219A1 |
The present invention relates to a modified microorganism of the genus Corynebacterium producing L-glutamic acid and a method for producing L-glutamic acid using same, more specifically to a novel variant of pantoate-beta-alanine ligase ...
|
|
WO/2024/097796A1 |
The present application provides methods of treating a complement-mediated disease in a human individual, comprising administering to the individual an effective amount of a fusion protein comprising i) an antibody moiety that specifical...
|
|
WO/2024/097877A1 |
Provided herein are ZP4 antibodies and ZP4-specific chimeric antigen receptors (CARs). Further provided herein are immune cells expressing the ZP4-specific CARs and methods of treating cancer by administering the ZP4-specific CAR immune ...
|
|
WO/2024/097892A1 |
This disclosure relates to introducing specified endogenous amiRNA responsive to endogenous primary-miRNAs. This invention allows the degradation of amiRNAs in specific tissues, while allowing amiRNA to silence gene expression in other t...
|
|
WO/2024/097243A1 |
Disclosed herein are yeast strains and derivatives thereof, as well as compositions comprising the yeast strains for use in ethanol manufacture. The disclosure also relates to processes for producing ethanol from biomass using the yeast ...
|
|
WO/2024/097418A2 |
Provided herein are gene activation and interference targets for exhaustion/dysfunction-resistant t cell products and uses thereof.
|
|
WO/2024/097829A1 |
Described herein are compositions for inhibiting a protease or coagulation target comprising a nucleic acid aptamer covalently linked to a small molecule inhibitor and methods for using the same to inhibit coagulation. Also provided are ...
|
|
WO/2024/094793A1 |
The present invention relates to the purification of linear DNA products, which may have nuclease-resistance. The linear DNA products may be double-stranded or single stranded. In addition, the present invention relates to purified linea...
|
|
WO/2024/097732A2 |
The present invention provides nucleic acid-loaded virus-like particles (VLPs) that can be produced in plants and are designed to deliver a nucleic acid into plant cells. Also provided are compositions comprising the nucleic acid-loaded ...
|
|
WO/2024/093790A1 |
The present application relates to the field of biotechnology, and in particular, to a stable and high-yield targeted integration cell, a method for preparing same, and use thereof. Compared with conventional techniques, the present appl...
|
|
WO/2024/094159A1 |
Provided in the present application are a single domain antibody targeting the ROR1 protein as well as a chimeric antigen receptor (CAR) and CAR-T cell comprising the single domain antibody. Also provided are uses of the single domain an...
|
|
WO/2024/092330A1 |
The present invention relates to nucleotide sequences that encode new truncated chimeric insecticidal proteins that exhibit inhibitory activity on lepidopterans. Particular embodiments provide compositions and plants, parts of parts, and...
|
|
WO/2024/097674A2 |
Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.
|
|
WO/2024/096124A1 |
The present disclosure provides a microorganism that inhibits oligomer formation of sgA. More specifically, the present disclosure provides a microorganism wherein at least one gene among the curli pili operon gene group, sigma factor ge...
|
|
WO/2024/092388A1 |
The present invention provides a nucleic acid loading reagent and a method for detecting the nucleic acid adsorption capacity of a sequencing chip using same. The method comprises at least one of the following conditions: (i) the nucleic...
|
|
WO/2024/094017A1 |
Provided are a GPC3 bispecific antigen binding molecule or an antigen binding fragment thereof, a derivative containing the bispecific antigen binding molecule or the antigen binding fragment thereof, and a pharmaceutical composition. In...
|
